Compare YieldMax MSTR Option Income Strategy ETF (MSTY) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax MSTR Option Income Strategy ETF vs 10X Genomics Inc — how do they compare? YieldMax MSTR Option Income Strategy ETF trades at $12.48, while 10X Genomics Inc trades at $58.8 (market cap $7.64B). The key difference: 10X Genomics Inc is trading nearer its 52-week high, YieldMax MSTR Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| MSTY | TXG | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $96.95 | $58.57 |
52-Week Low | $11.55 | $11.34 |
Market Cap | — | $7.64B |
Enterprise Value | — | $7.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTY (YieldMax MSTR Option Income Strategy ETF) trades at $12.82, up 2.31% today, but remains in a significant downtrend with a 67% decline year-to-date. The ETF faces structural challenges as high distribution yields mask substantial NAV erosion, with technical indicators showing neutral momentum amid bearish moving averages. Recent news highlights concerns about the fund returning investor capital as distributions while experiencing deep losses.
The outlook remains challenged by the ETF's structural limitations that cap upside potential while exposing investors to full downside risk. Investment opportunity exists only for sophisticated investors seeking high current income despite principal erosion, while risks include continued NAV decline, tax inefficiency, and dependence on MicroStrategy's volatile performance.
TXG is trading at $52.03, up 14.1% in the past 24 hours, reflecting strong momentum. The stock exhibits a bullish technical signal with moving averages supporting upward trends, while RSI levels suggest mild overbought conditions. Fundamentally, the company reported Q2 2026 revenue of $151 million, beating estimates, and has shown consistent earnings beats in recent quarters. Recent news highlights collaborations with Cleveland Clinic and the acquisition of Proteintech Genomics, expanding its multiomics capabilities and reinforcing growth prospects.
The outlook for TXG is cautiously optimistic, driven by earnings outperformance and strategic expansions, but risks include persistent net losses and high valuation multiples. Analyst consensus is mixed with a $46 price target, indicating potential downside from current levels. Investors should weigh revenue growth against profitability challenges and monitor execution on new initiatives for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About YieldMax MSTR Option Income Strategy ETF
MSTY is an actively managed ETF that pursues a synthetic covered call strategy on MicroStrategy Incorporated (MSTR) stock. The fund primarily sells call options on MSTR and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the volatile, Bitcoin-correlated growth potential of MSTR while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on MSTY →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
